Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.

Authors

• Jaume Capdevila
• Jolanta Krajewska
• Jorge Hernando
• Bruce Robinson
• Steven I Sherman
• Barbara Jarzab
• Chia-Chi Lin
• Fernanda Vaisman
• Ana O Hoff
• Erika Hitre
• Daniel W Bowles
• Denise Williamson
• Roman Levytskyy
• Jennifer Oliver
• Bhumsuk Keam
• Marcia S Brose

Publication/Presentation Date

3-1-2024

Volume

34

Issue

3

First Page

347

Last Page

359

ISSN

1557-9077

Published In/Presented At

Capdevila, J., Krajewska, J., Hernando, J., Robinson, B., Sherman, S. I., Jarzab, B., Lin, C. C., Vaisman, F., Hoff, A. O., Hitre, E., Bowles, D. W., Williamson, D., Levytskyy, R., Oliver, J., Keam, B., & Brose, M. S. (2024). Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid : official journal of the American Thyroid Association, 34(3), 347–359. https://doi.org/10.1089/thy.2023.0463

Disciplines

Medicine and Health Sciences

PubMedID

38062732

Department(s)

Hematology-Medical Oncology Division

Document Type

Article